Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis
Journal of Experimental Medicine · 02.03.2026 · 223 (3)
DOI: 10.1084/jem.20251760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 05.12.2025. Verfasst von Adrian Gervais und 35 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker …. Hauptthemen laut MEDLINE: Autoantibodies, Interferon Type I, Antibodies, Neutralizing, Herpes Simplex. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Agence Nationale de la Recherche, Ministry of Higher Education, Research, and Innovation.
Abstract (Originalsprache)
Fulminant viral hepatitis (FVH) is a devastating condition caused by hepatotropic viruses such as hepatitis A virus (HAV), hepatitis B virus (HBV), and HSV-1/2. We studied 149 FVH patients (73 males and 76 females, aged 1–76) for blood autoantibodies (auto-Abs) neutralizing type I interferons (IFNs; IFN-α2, -β, -ω). Six of 16 (37.5%) HSV-triggered FVH patients carried such auto-Abs on admission, including three with a previously known autoimmune disease. These patients contrasted with 133 HAV- (n = 46) or HBV-triggered (n = 87) patients, none of whom had such detectable auto-Abs. Odds ratios for HSV-triggered FVH in individuals with auto-Abs ranged from 35.3 (95% CI: 13.0–96.2; P < 10–7) for those neutralizing only 100 pg/ml IFN-α/ω to 1,895 (CI: 448.5–8,002; P < 10–12) for those neutralizing both IFN-α and IFN-ω at 10 ng/ml. Over one third of HSV-triggered FVH cases in this international cohort were due to preexisting auto-Abs. This finding highlights auto-Abs against type I IFNs as a major determinant of HSV-FVH and paves the way for targeted preventive or therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children , Paris, France.
- Paris Cité University, Imagine Institute , Paris, France.
- Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- Department of Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
- Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
- McDermott Center for Human Growth and Development, UT Southwestern Medical Center , Dallas, TX, USA.
ORCID-Profile: Adrian Gervais, Astrid Marchal, Soraya Boucherit, Anthony Abi Haidar, Lucy Bizien, Ahmet Yalcinkaya, Ella Sandström, Xiao-Fei Kong, Emmanuel Jacquemin, Dominique Debray, Florence Lacaille, Philippe Ichai, Cigdem Arikan, Etienne Javouhey, Bertrand Roquelaure, Frédéric Gottrand, Francesca Trespidi, Veronica Codullo, Lorenzo Cavagna, Nicolas Schleinitz, Mohamed Bousfiha, Naima Amenzoui, Ahmed Aziz Bousfiha, Sofie E Jørgensen, Nanna Mørk, Trine H Mogensen, Paul Bastard, Anne Puel, Alessandro Borghesi, Jody A Rule, William M Lee, Nils Landegren, Aurélie Cobat, Jean-Laurent Casanova, Emmanuelle Jouanguy
Förderung
- NIDDK NIH HHS
- Agence Nationale de la Recherche
- Ministry of Higher Education, Research, and Innovation
- San Matteo Hospital
- General Atlantic Foundation
- National Institute of Diabetes Digestive and Kidney Diseases
- HORIZON-HLTH-2021-DISEASE-04
- French Foundation for Medical Research
Zitieren
APA
Gervais, A., Marchal, A., Boucherit, S., Abi Haidar, A., Bizien, L., Yalcinkaya, A., Sandström, E., Kong, X. F., Jacquemin, E., Bernard, O., Debray, D., Lacaille, F., Ichai, P., Arikan, C., Javouhey, E., Roquelaure, B., Gottrand, F., Trespidi, F., Codullo, V., …, & Jouanguy, E. (2026). Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis. Journal of Experimental Medicine, 223(3). https://doi.org/10.1084/jem.20251760
Vancouver
Gervais A, Marchal A, Boucherit S, Abi Haidar A, Bizien L, Yalcinkaya A, et al. Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis. Journal of Experimental Medicine. 2026;223(3). doi:10.1084/jem.20251760
BibTeX
@article{Gervais2026,
author = {Gervais, Adrian and Marchal, Astrid and Boucherit, Soraya and Abi Haidar, Anthony and Bizien, Lucy and Yalcinkaya, Ahmet and Sandström, Ella and Kong, Xiao-Fei and Jacquemin, Emmanuel and Bernard, Olivier and Debray, Dominique and Lacaille, Florence and Ichai, Philippe and Arikan, Cigdem and Javouhey, Etienne and Roquelaure, Bertrand and Gottrand, Frédéric and Trespidi, Francesca and Codullo, Veronica and Cavagna, Lorenzo and Schleinitz, Nicolas and Bousfiha, Mohamed and Amenzoui, Naima and Bousfiha, Ahmed Aziz and Jørgensen, Sofie E and Mørk, Nanna and Mogensen, Trine H and Bastard, Paul and Puel, Anne and Borghesi, Alessandro and Rule, Jody A and Lee, William M and Landegren, Nils and Cobat, Aurélie and Casanova, Jean-Laurent and Jouanguy, Emmanuelle},
title = {Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {3},
doi = {10.1084/jem.20251760}
}
EUVIMED